WO2012156473A3 - Série de micro-arn comme marqueurs et cibles dans le cancer et les maladies liées au système immunitaire, procédés d'application et trousse - Google Patents

Série de micro-arn comme marqueurs et cibles dans le cancer et les maladies liées au système immunitaire, procédés d'application et trousse Download PDF

Info

Publication number
WO2012156473A3
WO2012156473A3 PCT/EP2012/059186 EP2012059186W WO2012156473A3 WO 2012156473 A3 WO2012156473 A3 WO 2012156473A3 EP 2012059186 W EP2012059186 W EP 2012059186W WO 2012156473 A3 WO2012156473 A3 WO 2012156473A3
Authority
WO
WIPO (PCT)
Prior art keywords
targets
micrornas
markers
cancer
immune system
Prior art date
Application number
PCT/EP2012/059186
Other languages
English (en)
Other versions
WO2012156473A2 (fr
Inventor
Ana REBANE
Liina TSEREL
Toomas RUNNEL
Kai KISAND
Maire PIHLAP
Original Assignee
University Of Tartu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Tartu filed Critical University Of Tartu
Publication of WO2012156473A2 publication Critical patent/WO2012156473A2/fr
Publication of WO2012156473A3 publication Critical patent/WO2012156473A3/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B26—HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26D—CUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D3/00—Cutting work characterised by the nature of the cut made; Apparatus therefor
    • B26D3/18—Cutting work characterised by the nature of the cut made; Apparatus therefor to obtain cubes or the like
    • B26D3/185—Grid like cutters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B26—HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26D—CUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D5/00—Arrangements for operating and controlling machines or devices for cutting, cutting-out, stamping-out, punching, perforating, or severing by means other than cutting
    • B26D5/08—Means for actuating the cutting member to effect the cut
    • B26D5/10—Hand or foot actuated means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B26—HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26D—CUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D3/00—Cutting work characterised by the nature of the cut made; Apparatus therefor
    • B26D3/18—Cutting work characterised by the nature of the cut made; Apparatus therefor to obtain cubes or the like
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B26—HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26D—CUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D5/00—Arrangements for operating and controlling machines or devices for cutting, cutting-out, stamping-out, punching, perforating, or severing by means other than cutting
    • B26D5/08—Means for actuating the cutting member to effect the cut
    • B26D5/18—Toggle-link means
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B26—HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26D—CUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D7/00—Details of apparatus for cutting, cutting-out, stamping-out, punching, perforating, or severing by means other than cutting
    • B26D7/06—Arrangements for feeding or delivering work of other than sheet, web, or filamentary form
    • B26D7/0608—Arrangements for feeding or delivering work of other than sheet, web, or filamentary form by pushers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B26—HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26D—CUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D7/00—Details of apparatus for cutting, cutting-out, stamping-out, punching, perforating, or severing by means other than cutting
    • B26D7/18—Means for removing cut-out material or waste
    • B26D7/1818—Means for removing cut-out material or waste by pushing out
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Forests & Forestry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne la détection de l'expression différentielle de micro-ARN (miARN) spécifiques dans certaines conditions biologiques/ pathologiques, et les applications fonctionnelles du miR-511, miR-193b, miR-99b et autres miARN indiqués comme marqueurs et cibles dans le cancer et les maladies liées au système immunitaire. Les miARN sont utilisés comme cibles de modulation d'expression pour influencer les propriétés prolifératives d'une cellule et/ou les fonctions immunes d'un organisme.
PCT/EP2012/059186 2011-05-16 2012-05-16 Série de micro-arn comme marqueurs et cibles dans le cancer et les maladies liées au système immunitaire, procédés d'application et trousse WO2012156473A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EEP201100037 2011-05-16
EEP201100037A EE201100037A (et) 2011-05-16 2011-05-16 MikroRNAde kasutamine biomarkeritena ja sihtm„rkidena raku proliferatiivsete omaduste m?jutamiseks ja meetod ning komplekt nende ekspressioonitaseme tuvastamiseks

Publications (2)

Publication Number Publication Date
WO2012156473A2 WO2012156473A2 (fr) 2012-11-22
WO2012156473A3 true WO2012156473A3 (fr) 2013-03-07

Family

ID=45937266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/059186 WO2012156473A2 (fr) 2011-05-16 2012-05-16 Série de micro-arn comme marqueurs et cibles dans le cancer et les maladies liées au système immunitaire, procédés d'application et trousse

Country Status (2)

Country Link
EE (1) EE201100037A (fr)
WO (1) WO2012156473A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957894A (zh) * 2016-01-11 2017-07-18 中国医学科学院肿瘤医院 microRNA分子表达谱用于预测非小细胞肺癌脑转移风险的用途
CN107137701B (zh) * 2017-05-07 2020-07-14 山东兴瑞生物科技有限公司 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗
CN108125976B (zh) * 2017-12-29 2020-07-31 唐山市人民医院 预测肺癌脑转移分子标记物miR-4270及在药物和诊断试剂盒中的应用
CN111053789A (zh) * 2019-11-26 2020-04-24 湖南营养树生物科技有限公司 调节免疫系统的方法和组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028967A2 (fr) * 2004-09-02 2006-03-16 Yale University Regulation d'oncogenes par des micro-arn
WO2006137941A2 (fr) * 2004-11-12 2006-12-28 Ambion, Inc. Procedes et compositions comprenant des molecules de micro-arn et des molecules d'inhibiteur de micro-arn
WO2010056737A2 (fr) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Procédés et compositions impliquant des miarn dans des cellules souches cancéreuses
WO2010129919A1 (fr) * 2009-05-08 2010-11-11 Research Development Foundation Expression d'arnmi dans une maladie allergique
WO2011025919A1 (fr) * 2009-08-28 2011-03-03 Asuragen, Inc. Biomarqueurs de micro-arn de maladie pulmonaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004032196A1 (de) 2004-07-02 2006-02-02 Strasser, Wolfgang, Dr.med. Testkit und Haftklebeband für eine zytologische Untersuchung der Hautoberfläche
US9394538B2 (en) 2008-05-07 2016-07-19 Shi-Lung Lin Development of universal cancer drugs and vaccines
JP5513375B2 (ja) 2008-05-07 2014-06-04 北海道公立大学法人 札幌医科大学 癌の検出方法および検出用キット、ならびに癌治療剤
ITMI20091538A1 (it) 2009-09-07 2011-03-08 Istituto Naz Di Genetica Mole Colare Ingm Profili di espressione di micro-rna nel sangue periferico di pazienti affetti da epatocarcinoma o cirrosi epatica e loro usi

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028967A2 (fr) * 2004-09-02 2006-03-16 Yale University Regulation d'oncogenes par des micro-arn
WO2006137941A2 (fr) * 2004-11-12 2006-12-28 Ambion, Inc. Procedes et compositions comprenant des molecules de micro-arn et des molecules d'inhibiteur de micro-arn
WO2010056737A2 (fr) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Procédés et compositions impliquant des miarn dans des cellules souches cancéreuses
WO2010129919A1 (fr) * 2009-05-08 2010-11-11 Research Development Foundation Expression d'arnmi dans une maladie allergique
WO2011025919A1 (fr) * 2009-08-28 2011-03-03 Asuragen, Inc. Biomarqueurs de micro-arn de maladie pulmonaire

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CEPPI M ET AL.: "MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 106, 24 February 2009 (2009-02-24), pages 2735 - 2740, XP002681809 *
FULCI V ET AL.: "Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia", BLOOD, vol. 109, 1 June 2007 (2007-06-01), pages 4944 - 4951, XP002681810 *
KIM T H ET AL.: "Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours", HISTOPATHOLOGY, vol. 57, 2010, pages 734 - 743, XP002681808 *
LODISH H F ET AL.: "Micromanagement of the immune system by microRNAs", NATURE REVIEWS IN IMMUNOLOGY, vol. 8, 2008, pages 120 - 130, XP002681811 *
MATTES JOERG ET AL: "Regulation of microRNA by antagomirs: a new class of pharmacological antagonists for the specific regulation of gene function?", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 36, no. 1, 1 January 2007 (2007-01-01), pages 8 - 12, XP009086371, ISSN: 1044-1549, DOI: 10.1165/RCMB.2006-0227TR *
SHAO W ET AL: "Combined Application of Blocking Antibodies and MicroRNA Interference in Inhibiting CD44 Expression", TRANSPLANTATION PROCEEDINGS, ELSEVIER INC, ORLANDO, FL; US, vol. 42, no. 7, 1 September 2010 (2010-09-01), pages 2777 - 2781, XP027272931, ISSN: 0041-1345, [retrieved on 20100909] *
SHEEDY F J ET AL: "Adding fuel to fire: microRNAs as a new class of mediators of inflammation", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 67, no. Suppl 3, 1 December 2008 (2008-12-01), pages 11150 - 11155, XP009122257, ISSN: 0003-4967, DOI: 10.1136/ARD.2008.100289 *
TAGANOV KONSTANTIN D ET AL: "NF-.kappa.B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 103, no. 33, 15 August 2006 (2006-08-15), pages 12481 - 12486, XP002544549, ISSN: 0027-8424, DOI: 10.1073/PNAS.0605298103 *
TSEREL L ET AL.: "MicroRNA expression profiles of human blood monocyte-derived dendritic cells and macrophages reveal miR-511 as putative positive regulator of Toll-like receptor 4", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 30, 29 July 2011 (2011-07-29), pages 26487 - 26495, XP002681812 *

Also Published As

Publication number Publication date
WO2012156473A2 (fr) 2012-11-22
EE201100037A (et) 2012-12-17

Similar Documents

Publication Publication Date Title
AU2018253607A1 (en) Novel class of glyphosate resistance genes
WO2012094492A3 (fr) Traceurs adn combinatoires et procédés de préparation et utilisation de ceux-ci
EP3008201A4 (fr) Procédés, nécessaires et systèmes pour détection multiplexe de molécules cibles et leurs utilisations
WO2012083969A3 (fr) Microarn pour le diagnostic du cancer du pancréas
AU2015329974A8 (en) GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
EP4223770A3 (fr) Nouvelles molécules de fusion et leurs utilisations
WO2013101902A3 (fr) Points polymères chromophores à émission à bande étroite
WO2011113030A3 (fr) Profils d'expression de micro-arn de cancer humain prédictifs de réponse à la chimiothérapie
WO2012056457A3 (fr) COMPOSITIONS ET PROCÉDÉS D'ACTIVATION D'EXPRESSION PAR UN ARNmi ENDOGÈNE SPÉCIFIQUE
WO2013158309A3 (fr) Ciblage génique non disruptif
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
WO2011094335A3 (fr) Signatures de microarn prédictives de la réponse à une thérapie anti-her2
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
WO2012078558A3 (fr) Micro-arn en tant que nouvelles cibles thérapeutiques pour la prévention et/ou le traitement de la rétinopathie
WO2011153431A3 (fr) Anticorps anti-sparc du sang périphérique et leurs utilisations
BR112014032940A2 (pt) ésteres de carboidratos como indutores de expressão de genes
WO2013177593A3 (fr) Identification d'antigènes phosphopeptidiques de cmh de classe i du cancer du sein à l'aide d'une technologie shla et de stratégies d'enrichissement complémentaires
WO2011097509A3 (fr) Signatures du gène associé à l'hypoxie pour la classification du cancer
WO2014145870A3 (fr) Nouvelles compositions, nouveaux procédés et nouvelles trousses permettant de déterminer le groupe sanguin
EP3365679B8 (fr) Procédés d'identification d'un individu devant être traité par chimiothérapie en se basant sur des molécules de marqueurs et utilisations associées
WO2012156473A3 (fr) Série de micro-arn comme marqueurs et cibles dans le cancer et les maladies liées au système immunitaire, procédés d'application et trousse
EP3679142A4 (fr) Systèmes d'acide nucléique qui permettent à des bactéries de cibler spécifiquement des tumeurs solides par l'intermédiaire d'une viabilité dépendante du glucose

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12727322

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12727322

Country of ref document: EP

Kind code of ref document: A2